BioXcel Therapeutics, Inc.

NASDAQ:BTAI

0.3511 (USD) • At close December 24, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202320222021202020192018201720162015
Revenue 1.380.3750000000
Cost of Revenue 1.260.020.2970.1880.1560.0170.00100
Gross Profit 0.120.355-0.297-0.188-0.156-0.017-0.00100
Gross Profit Ratio 0.0870.9470000000
Reseach & Development Expenses 84.32691.23952.70857.99525.79714.5582.691.3990.233
General & Administrative Expenses 63.51468.76154.22724.3027.8045.4041.8470.7210
Selling & Marketing Expenses 19.89913.0060000000
SG&A 83.41368.76154.22724.3027.8045.4041.8470.7210.403
Other Expenses 4.163-0.4270000000
Operating Expenses 171.902160106.93582.29733.60119.9624.5372.120.636
Operating Income -171.782-159.645-106.935-82.297-33.601-19.962-4.537-2.12-0.636
Operating Income Ratio -124.48-425.720000000
Total Other Income Expenses Net -7.271-6.112-0.3580.1280.6330.692-0.00200
Income Before Tax -179.053-165.757-106.931-82.169-32.968-19.27-4.539-2.12-0.636
Income Before Tax Ratio -129.749-442.0190000000
Income Tax Expense 06.092-0.301-0.161-0.6330.6920-2.120
Net Income -179.053-171.849-106.63-82.008-32.335-19.27-4.539-2.12-0.636
Net Income Ratio -129.749-458.2640000000
EPS -6.15-6.13-4.04-3.78-1.99-1.32-0.3-0.14-0.04
EPS Diluted -6.15-6.13-4.04-3.78-1.99-1.32-0.3-0.14-0.04
EBITDA -165.421-157.384-106.996-81.981-32.812-19.253-4.5360-0.636
EBITDA Ratio -119.87-420.1170000000